Safety and feasibility of neural transplantation in early to moderate Huntington's disease in the UK

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN36485475

Enrollment

Registered

2000-10-23

Start date

1999-10-01

Completion date

Unknown

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroscience, psychiatry Mental and Behavioural Disorders Huntington's disease

Interventions

Patients in matched pairs randomly allocated to experimental and control conditions

the pairs are selected from a larger research cohort undergoing longitudinal assessment but not (yet) selected for participation in the surgical trial. All subjects will be examined u

Eligibility

Inclusion criteria

Inclusion criteria: 1. Genetically confirmed Huntington's disease 2. Early to moderate stage of disease 3. Presence of motor signs 4. Availability of one close primary informant

Exclusion criteria

Exclusion criteria: 1. Advanced disease 2. Still employable in usual occupation 3. Other concurrent major illness 4. Current serious psychiatric disturbance 5. Inadequate social support 6. Below the age of 18

Design outcomes

Primary

Measure	Time frame
Safety trial: 1. Presence/absence of adverse events 2. Feasibility: a. co-ordination of an effective and efficient programme for foetal tissue collection b. biosafety assessment c. preparation and implantation into identified patients and their long term evaluation on the relevant structural and functional criteria of graft survival and efficacy Efficacy trial: Retardation or reversal of the progress of the disease in the affected patients as determined by the neurological, neuropsychological and neuropsychiatric and imaging criteria of neuropsychological tests of cognition using the CAmbridge Neuropsychological Test Automated Battery (CANTAB) test battery.	—

Measure

Time frame

Safety trial: 1. Presence/absence of adverse events 2. Feasibility: a. co-ordination of an effective and efficient programme for foetal tissue collection b. biosafety assessment c. preparation and implantation into identified patients and their long term evaluation on the relevant structural and functional criteria of graft survival and efficacy Efficacy trial: Retardation or reversal of the progress of the disease in the affected patients as determined by the neurological, neuropsychological and neuropsychiatric and imaging criteria of neuropsychological tests of cognition using the CAmbridge Neuropsychological Test Automated Battery (CANTAB) test battery.

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026